Valerie Brown
Beat Childhood Cancer
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Valerie Brown as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:45 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06540963 · Tipifarnib and Naxitamab for Relapsed/Refractory NeuroblastomaGiselle Sholler · recruiting · Neuroblastoma · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:45 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in neuroblastoma, ranked by citations from NIH iCite, fetched 2026-11-12 11:45 UTC. The ranking covers the 200 most relevant of 5 PubMed records, and a shared surname and initials can bring in a namesake. All 5 on PubMed
- 95 citationsRCR 3.4
- Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons.J Clin Oncol · 202460 citationsRCR 7.9
- A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high-risk neuroblastoma.Int J Cancer · 202053 citationsRCR 2.6
- Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trial.Genome Med · 202412 citationsRCR 1.4
- A phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and medulloblastoma.Int J Cancer · 20239 citationsRCR 0.9